Drugs / SAR443765
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05366764 | Jun 2022 → Feb 2023 | asthma | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR443765 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366764 ↗ |
| Action | Inhibit | “inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13” PMID 38924698 ↗ Jun 2024 |
| Route | Intravenous | “10-400 mg intravenous [IV] or 400 mg subcutaneous [SC]” PMID 38924698 ↗ Jun 2024 |
| Route | Subcutaneous | “10-400 mg intravenous [IV] or 400 mg subcutaneous [SC]” PMID 38924698 ↗ Jun 2024 |